On September 10, at FANGZHOU JIANKE's 10th H2H Medical Service Ecosystem Conference, leading AI-powered chronic disease management company FANGZHOU JIANKE (06086) officially signed a strategic cooperation agreement with INNOVENT BIO. Xie Fangmin, Founder, Chairman and CEO of FANGZHOU JIANKE, and Tan Zaiqiang, Retail Vice President of INNOVENT BIO's Omnichannel Business Division, jointly attended the signing ceremony.
This strategic partnership aims to integrate FANGZHOU JIANKE's digital intelligence service capabilities in AI-powered chronic disease management with INNOVENT BIO's innovative drug development advantages in metabolic diseases. Together, they seek to build a new digitally intelligent cooperation model combining "AI technology + innovative products + refined services," contributing innovative strength toward achieving the "Healthy China 2030" strategic goals.
The collaboration between FANGZHOU JIANKE and INNOVENT BIO comes at a crucial juncture as China's weight management market accelerates its development. According to JPMorgan Chase projections, China's weight loss drug market is expected to reach $14.9 billion (approximately 106.2 billion RMB) by 2030. From a policy perspective, in June 2024, the National Health Commission and 16 other departments formulated and released the "Weight Management Year" Activity Implementation Plan. In April 2025, the National Patriotic Health Campaign Committee issued a notice incorporating healthy weight management actions into the Healthy China initiative. This demonstrates that weight management has evolved from individual health behavior to an important issue in national public health governance.
Facing this billion-scale market opportunity, major pharmaceutical companies are actively positioning themselves to seize the initiative. In this blue ocean market, how to build differentiated advantages and explore new solutions and development models has become the industry's focal point.
Against this backdrop, the strategic cooperation between FANGZHOU JIANKE and INNOVENT BIO will focus on metabolic diseases such as diabetes and obesity, jointly promoting overall value enhancement in the weight management field.
FANGZHOU JIANKE will leverage its AI technological achievements, H2H intelligent medical ecosystem, and digital industry experience to reshape the full-cycle management process for chronic disease patients, creating a personalized, integrated health management experience. Based on its proprietary Xingshi Medical Large Model, the company has completed a full-chain upgrade of its platform ecosystem, developing five major AI products: AI Medication Finder, AI Health Manager, AI Doctor's Assistant, AI Academic Assistant, and AI-Powered Search.
As an outstanding representative of China's innovative pharmaceutical companies, INNOVENT BIO has grown into a globally leading biopharmaceutical enterprise through over a decade of development, leveraging its innovative research and development achievements. The company currently possesses 16 commercialized products, over 30 product pipelines, and a commercial network covering more than 300 cities. Research indicates that its next-generation weight loss drug Mazdutide can significantly reduce body weight while improving multiple health indicators including blood pressure, blood lipids, and uric acid. This innovative drug has also been selected as one of the top 10 anticipated global drugs for 2025.
Based on this strategic cooperation's positive foundation, both parties will leverage their respective advantages to promote deep integration of innovative treatment solutions with AI technology-driven digital health management, jointly building a new service paradigm in the "AI + weight management" field.
Specifically, in pharmaceutical services, leveraging the real-time response capabilities of the AI Medication Finder, obesity patients can receive 24/7 online consultation, medication sourcing, and medication Q&A professional support without waiting, completely breaking through traditional pharmaceutical service time and space limitations.
In weight management, the AI Health Manager serves as patients' round-the-clock health management partner, providing personalized medication guidance, service reminders and management, report interpretation, and knowledge education extension services. This not only provides psychological comfort but also reduces decision-making costs, effectively enhancing patients' health literacy and self-management capabilities.
Dr. Xie Fangmin, Founder, Chairman and CEO of FANGZHOU JIANKE, stated: "We are delighted to reach this strategic cooperation with INNOVENT BIO. Our company has always been committed to improving the accessibility of internet medical and health services through AI technology applications. INNOVENT BIO's innovative achievements in metabolic diseases are highly complementary to our digital intelligence service capabilities. We look forward to exploring new models that deeply integrate innovative drugs with digital health services through this cooperation."
Looking ahead, FANGZHOU JIANKE and INNOVENT BIO will continue to deepen their exploration in digital health management, helping to enhance China's chronic disease management service levels and treatment accessibility, providing more patients with more efficient, precise, and convenient health management service experiences.